Seuthe Anna-Maria, Ivanescu Ciprian, Leers Stephan, Boden Karl, Januschowski Kai, Szurman Peter
Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, An der Klinik 10, 66280, Sulzbach, Saar, Germany.
Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1591-1597. doi: 10.1007/s00417-016-3370-6. Epub 2016 May 10.
The aim of this study was to investigate the efficacy and safety of a new and modified canaloplasty technique with suprachoroidal drainage in a large patient cohort, and to compare its IOP-lowering and topical drug-sparing effect to that of conventional canaloplasty.
This retrospective clinical trial included patients with open-angle glaucoma or secondary forms of glaucoma who underwent either conventional canaloplasty or canaloplasty with suprachoroidal drainage. Primary endpoint was the IOP reduction after 12 months as well as the number of IOP-lowering medications. Secondary endpoints were intra- and postoperative complications and the occurrence of secondary surgical interventions.
Four hundred and seventeen eyes were included in the study; 180 of them were treated with conventional canaloplasty, and 237 eyes underwent canaloplasty with suprachoroidal drainage. In both groups, a significant IOP reduction could be observed after 12 months. Mean IOP reduction was stronger after canaloplasty with suprachoroidal drainage (35.9 %) (from baseline 20.9 ± 3.5 mmHg to 13.1 ± 2.5 mmHg) than after conventional canaloplasty (31.2 %) (from baseline 20.8 ± 3.6 mmHg to 14.0 ± 2.6 mmHg) (p < 0.01). The number of IOP-lowering medications decreased significantly in both groups: after canaloplasty with suprachoroidal drainage from 3.5 ± 0.9 to 0.7 ± 1.0, and after conventional canaloplasty from 3.4 ± 0.9 to 0.8 ± 0.9 with different drugs. The percentage of patients who were free of IOP-lowering agents after 1 year was significantly higher in the combined group (56.9 %) than in the group of conventional canaloplasty (45.4 %) (p = 0.0383). No serious complications were observed.
The modified surgery technique of canaloplasty with suprachoroidal drainage yields the opportunity to optimize the IOP-lowering effect of canaloplasty as a non-penetrating surgical procedure while still offering a more favourable safety profile than trabeculectomy. The suprachoroidal access facilitates the most complicated step of the canaloplasty surgery: the localization of Schlemm's canal.
本研究旨在调查一种新的改良小梁切开术联合脉络膜上腔引流技术在大量患者队列中的疗效和安全性,并将其降低眼压和减少局部用药的效果与传统小梁切开术进行比较。
这项回顾性临床试验纳入了接受传统小梁切开术或小梁切开术联合脉络膜上腔引流的开角型青光眼或继发性青光眼患者。主要终点是12个月后的眼压降低情况以及降低眼压药物的数量。次要终点是术中及术后并发症以及二次手术干预的发生情况。
该研究共纳入417只眼;其中180只眼接受了传统小梁切开术,237只眼接受了小梁切开术联合脉络膜上腔引流。两组在12个月后眼压均显著降低。小梁切开术联合脉络膜上腔引流术后平均眼压降低幅度更大(35.9%)(从基线的20.9±3.5mmHg降至13.1±2.5mmHg),高于传统小梁切开术(31.2%)(从基线的20.8±3.6mmHg降至14.0±2.6mmHg)(p<0.01)。两组降低眼压药物的数量均显著减少:小梁切开术联合脉络膜上腔引流术后从3.5±0.9降至0.7±1.0,传统小梁切开术后从3.4±0.9降至0.8±0.9,使用的药物不同。联合组1年后无需使用降低眼压药物的患者百分比(56.9%)显著高于传统小梁切开术组(45.4%)(p=0.0383)。未观察到严重并发症。
改良的小梁切开术联合脉络膜上腔引流手术技术有机会优化小梁切开术作为一种非穿透性手术的降眼压效果,同时仍比小梁切除术具有更有利的安全性。脉络膜上腔入路有助于小梁切开术最复杂的步骤:施莱姆管的定位。